First Medicine Specifically Targeting BRCA Mutations to Demonstrate Statistically Significant Improvement in Invasive Disease-Free Survival in Adjuvant Setting Following Definitive Local Treatment and Neoadjuvant or Adjuvant ChemotherapyKENILWORTH, N.J.--(BUSINESS WIRE)--$MRK #MRK--AstraZeneca and Merck (NYSE: MRK),...